Kala Bio (FRA:27F0) Debt-to-Asset : 0.65 (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Kala Bio Debt-to-Asset?

Kala Bio's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.31 Mil. Kala Bio's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €33.00 Mil. Kala Bio's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was €51.31 Mil. Kala Bio's debt to asset for the quarter that ended in Dec. 2023 was 0.65.

Kala Bio Debt-to-Asset Historical Data

The historical data trend for Kala Bio's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kala Bio Debt-to-Asset Chart

Kala Bio Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.66

0.46

0.58

0.50

0.65

Kala Bio Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Asset	Get a 7-Day Free Trial															0.50	0.46	0.51	0.59	0.65

Competitive Comparison of Kala Bio's Debt-to-Asset

For the Biotechnology subindustry, Kala Bio's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kala Bio's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kala Bio's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Kala Bio's Debt-to-Asset falls into.

Kala Bio Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Kala Bio's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.306	+	33.002)	/	51.305
	=	0.65

Kala Bio's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.306	+	33.002)	/	51.305
	=	0.65

Kala Bio (FRA:27F0) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Kala Bio Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Kala Bio's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Kala Bio (FRA:27F0) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kala Bio Inc (FRA:27F0) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

KALA:USA 27F0:Germany

Address

1167 Massachusetts Avenue, Arlington, MA, USA, 02476

Website

https://www.kalarx.com

Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing innovative therapies for rare and severe eye diseases. KALA's lead product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.

Kala Bio (FRA:27F0) Headlines

No Headlines